Biogen Inc. (BIIB)
SIX
Real-time Data
07:00 AM
Day's Range
173.4652 wk Range
131.09Overview - BIIB - Biogen Inc.
Key Statistics
Valuation
Enterprise Value
27.15B
P/E (Trailing)
‪30.79‬
PEG Ratio
‪-0.36‬
Price / Sales (TTM)
‪2.07‬
Price / Book
‪1.36‬
EV / EBITDA
‪9.97‬
Profitability
Gross Margin
‪71.60%‬
Profit Margin
‪8.32%‬
Operating Margin
‪25.05%‬
Return on Assets
‪5.20%‬
Return on Equity
‪4.57%‬
Ownership
Shares Outstanding
147.70M
Float
147.29M
Held by Insiders
‪0.18%‬
Held by Institutions
‪96.35%‬
Price stats
Beta
‪0.16‬
50-Day Avg
‪165.07‬
200-Day Avg
‪153.84‬
Dividends
Payout Ratio
‪0.00%‬
Shariah Compliance
Report Date: Feb 16, 2025
Screened by Zoya using the AAOIFI methodology.
Peers - BIIB - Biogen Inc.
Peer Comparison
Compared with companies in Drug Manufacturers - General listed on SIX.
Profile Summary - BIIB - Biogen Inc.
About
Biogen Inc. is a biotechnology company that discovers, develops, manufactures, and delivers therapies for treating neurological and neurodegenerative diseases in the United States, Europe, Germany, Asia, and internationally. The company offers products such as TECFIDERA, VUMERITY, AVONEX, PLEGRIDY, and TYSABRI for…
The information on this page is provided for general informational purposes only and is not investment advice.
Market data provided by Twelve Data. Shariah compliance data provided by Zoya. Charting by TradingView.
Last updated:
